FDA Downgrades Fibromyalgia Therapy Device to Class II
Published Date: 6/26/2026
Rule
Summary
The FDA is officially classifying a computerized behavioral therapy device for fibromyalgia symptoms as a Class II device, meaning it meets safety and effectiveness standards with special controls. This change helps patients get easier access to this innovative treatment by reducing some regulatory hurdles. The new classification is effective June 26, 2026, and could speed up how quickly these devices reach the market without extra costs.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 2 costs, 1 mixed.
Device Reclassified to Class II — Easier Access
The FDA officially classified the computerized behavioral therapy device for treatment of fibromyalgia symptoms as Class II with special controls, effective June 26, 2026 (classification applicable May 9, 2023). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
510(k) Premarket Notification Is Required
FDA states that computerized behavioral therapy devices for fibromyalgia symptoms are subject to premarket notification requirements under section 510(k) of the FD&C Act (they have not been exempted under section 510(m)). Manufacturers must therefore submit a 510(k) to market these Class II devices.
New Special Controls: Clinical Data, Software, Labeling
FDA set special controls for this device type: clinical data must evaluate improvement in fibromyalgia symptoms and relevant adverse events; software verification, validation, and hazard analysis are required; and physician and patient labeling must include recommended treatment regimes (frequency and duration) and a summary of clinical data including adverse events.
Sets Predicate for Future Devices — Easier 510(k) Route
FDA states that when a device is classified into class II through the De Novo process, that device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process instead of a De Novo or PMA. This can reduce regulatory burdens for future device sponsors.
Prescription-Only Requirement Maintained
At the time of classification, the computerized behavioral therapy device for fibromyalgia symptoms is a prescription device intended to provide a computerized version of behavioral therapy. Prescription devices remain subject to prescription-only conditions and related labeling rules.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12899 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Previous / Next Documents
Previous: 2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Next: 2026-12902 — Medical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Test
The FDA is officially putting the COVID-19 antibody (serology) test into a safer, easier-to-manage category called Class II, starting June 26, 2026. This change helps make sure the tests work well and are safe, while also making it simpler for companies to bring new and better tests to patients. If you’re a test maker or user, expect smoother rules and better access without extra costs or delays.